Kardionat caps. 250mg 40 pieces


Kardionat caps. 250mg 40 pieces



Active substance:
Meldonium dihydrate (trimethylhydrasine propionate dihydrate) based on the dihydrate without adsorbed moisture – 250 mg.
Potato starch 13.3 mg. colloidal silicon dioxide (Aerosil) 5.7 mg. Calcium stearate 2.7 mg: capsule (gelatine, titanium dioxide).
Hard gelatin capsules № 1 of white color. Contents of capsules – white or almost white crystalline powder with a faint odor. Hygroscopic powder, may be clumping.
Product form:
Capsules 250 mg.
10 capsules in blisters of PVC film and aluminum foil.
4 the contour of cellular packaging together with instructions for use in a pile of cardboard.
Hypersensitivity to main and / or auxiliary components of the drug; increased intracranial pressure (in violation of the venous outflow and intracranial tumors); pregnancy; breastfeeding; age 18 years (effectiveness and safety have been established).
250 mg
Reduced performance; mental and physical (including athletes) overload.
In the complex treatment of ischemic heart disease (angina), congestive heart failure, kardialgiya on background dyshormonal myocardial dystrophy.
In the combined therapy: ischemic (ischemic stroke, chronic cerebrovascular insufficiency).
Abstinence in chronic alcoholism (in the complex specific therapy).
Interaction with other drugs
It can be combined with antianginal drugs, anticoagulants, antiplatelet agents. antiarrhythmic drugs and the means and. Diouri and geeks. bronchodilators. It enhances the action vasodilatig, some antihypertensive drugs, cardiac glycosides. When combined with nitroglycerin, nifedipine, alpha-blockers. other antihypertensive drugs and drugs and peripheral vasodilators caution because of the possible development of moderate tachycardia and hypotension.
Symptoms: decrease in blood pressure accompanied by headache, palpitations, dizziness, general weakness.
Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
Metabolic means.
Synthetic analog of gamma-butyrobetaine, gamma butirobetaingidroksilazu inhibits, reduces the synthesis of carnitine and transportation of long chain fatty acids across cell membranes and prevents the accumulation of cells in the activated forms of unoxidized fatty acids – acylcarnitine derivatives and atsilkofermenta A. As a result of reducing the concentration of carnitine intensively synthesized gamma-butyrobetaine, having vasodilating properties. In conditions of ischemia meldonium it restores the balance of oxygen delivery and consumption processes in cells, prevents the transport violation of adenosine triphosphate (ATP) at the same time activates glycolysis, which occurs without additional oxygen consumption.
The mechanism of action defines the variety of pharmacological effects meldonium: improving efficiency, reducing the symptoms of mental and physical stress, activation of the immune system, cardioprotective effect. In the case of acute myocardial ischemic injury inhibits the formation of necrotic areas reduces the rehabilitation period. In heart failure, myocardial contractility increases, increases exercise tolerance: reduces the frequency of angina attacks.
In acute and chronic ischemic disorders of cerebral blood circulation improves blood circulation in the ischemic focus, promotes redistribution of blood to the ischemic area.
Characteristically a tonic effect on the central nervous system, elimination of functional disturbances of the vegetative part of the nervous system during abstinence syndrome in patients with chronic alcoholism.
After intake of rapidly absorbed from the gastrointestinal tract, bioavailability – 78%. The maximum plasma concentration is reached after 1-2 hours. It is metabolized in the body into two major metabolites are excreted by the kidneys. The half-life depends on dose and is 3-6 hours.
Pregnancy and breast-feeding
Safety of use during pregnancy has not been proved. To avoid possible adverse effects on the fetus during pregnancy, the drug is not prescribed.
It is unknown whether meldonium excreted in breast milk. If necessary, use Kardionat® during lactation should stop breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Cardio-vascular system: tachycardia, decreased or increased blood pressure.
On the part of the gastrointestinal tract: dyspepsia.
Central nervous system: agitation.
Allergic reactions: redness and itching of the skin, rash, swelling.
Other: eosinophilia, general weakness.
special instructions
In the treatment of patients with chronic liver diseases and kidney caution, especially with prolonged use of the drug.
Insufficient data on the use in children.
Effect on the ability to drive mechanisms and
No data on the adverse effects of the drug Kardionat® on ability to drive and use machines.
Storage conditions
In a dry place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside. The capsules should be swallowed whole, washed down with water.
In view of the possible effect of the exciting drug is recommended in the first half of the day.
Reduced performance, mental and physical stress – 500 mg (2 capsules), 2 times per day. The course of treatment – 10 – 14 days. If necessary, repeat the treatment after 2 – 3 weeks.
Athletes – 500 mg – 1.0 g of (2 – 4 capsules), 2 times a day before training. Duration of the course in the preparatory period of training – 14 – 21 days, in the period of the competition – 10 – 14 days.
Coronary heart disease (angina), congestive heart failure – 500 mg – 1.0 g of (2 – 4 capsules) per day, applying the entire dose at once or by dividing it into 2 doses. The course of treatment – 4 – 6 weeks.
Cardialgia at dyshormonal myocardiodystrophy – 250 mg 2 times a day. The course of treatment – 12 days.
Cerebrovascular accident.
In ischemic stroke – after a 10-day course of therapy injectable form Kardionat® transferred to the patient the drug intake of the drug in capsules of 500 mg – 1.0 g of (2 – 4 capsules) per day, taking the entire dose at once or by dividing it into 2 doses. The total course of treatment – 4 – 6 weeks. In chronic cerebrovascular insufficiency – 500 mg (2 capsules) per day. The course of treatment – 2 – 3 weeks. The need for repeated courses of treatment (2-3 times per year) is determined by the doctor.
State abstinent chronic alcoholism – 500 mg (2 capsules) four times a day. The course of treatment – 7 – 10 days.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review